Detailed instructions for usage and dosage standards and adjustment plans of amivantamab

Amivantamab (amivantamab) is a bispecific antibody mainly used to treat patients with non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Its unique structure can simultaneously target EGFR and MET receptors, block the signal transduction of tumor cells, and achieve the effect of inhibiting tumor growth. Correct usage and dosage and reasonable adjustments are crucial to ensure efficacy and reduce the risk of side effects.

For standard usage, evantumumab is administered by intravenous infusion. The first dose is usually given in two doses, with separate infusions on the first and second days to reduce the risk of infusion-related reactions. This is followed by weekly intravenous infusions, usually for four weeks, followed by a maintenance phase of infusions every two weeks. The specific dosage is calculated based on the patient's weight and body surface area, and is generally between 1050mg and 1400mg to ensure that the drug concentration is stable and achieves the therapeutic effect.

Dose adjustment is mainly based on the patient's tolerance and the degree of adverse reactions. If the patient experiences mild or moderate adverse reactions, it is usually recommended to temporarily interrupt the medication, resume treatment after the symptoms subside, and adjust the dose appropriately. For serious adverse reactions, such as severe infusion reactions, skin toxicity or other life-threatening events, the drug should be stopped immediately and corresponding treatment should be carried out. After the condition stabilizes, consideration should be given to whether to resume treatment and adjust the dosage.

In addition, patients should be regularly evaluated and monitored by doctors during treatment, including routine blood tests, liver and kidney function and imaging tests, in order to promptly detect side effects and evaluate efficacy. The medical team should pay close attention to infusion reactions and take preventive measures, such as pre-administration of anti-allergic drugs, to ensure patient safety. In short, reasonable usage and dosage and individualized adjustment plans are the keys to the safe and efficient application of evantumumab.

Reference materials:https://www.drugs.com

xa0